Below are the most recent publications written about "Vaccines, DNA" by people in Profiles.
-
Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prev Res (Phila). 2023 03 01; 16(3):163-173.
-
Oliveira-da-Silva JA, Machado AS, Ramos FF, Tavares GSV, Lage DP, Mendon?a DVC, Pereira IAG, Santos TTO, Martins VT, Carvalho LM, Freitas CS, Ludolf F, Reis TAR, Bandeira RS, Silva AM, Costa LE, Oliveira JS, Duarte MC, Roatt BM, Teixeira AL, Coelho EAF. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis. Cell Immunol. 2020 10; 356:104194.
-
Oliveira-da-Silva JA, Lage DP, Ramos FF, Machado AS, Tavares GSV, Mendon?a DVC, Pereira IAG, Martins VT, Carvalho LM, Ludolf F, Santos TTO, Reis TAR, Oliveira CS, Bandeira RS, Silva AM, Costa LE, Oliveira JS, Duarte MC, Menezes-Souza D, Roatt BM, Teixeira AL, Coelho EAF. Leishmania infantum pyridoxal kinase evaluated in a recombinant protein and DNA vaccine to protects against visceral leishmaniasis. Mol Immunol. 2020 08; 124:161-171.
-
Santos S, Ram?rez M, Miranda E, Reyes N, Mart?nez O, Acosta-Santiago M, Rivera JM, Otero M. Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious Diseases. J Immunol Res. 2019; 2019:3409371.
-
Ribeiro PAF, Dias DS, Lage DP, Martins VT, Costa LE, Santos TTO, Ramos FF, Tavares GSV, Mendon?a DVC, Ludolf F, Gomes DA, Rodrigues MA, Ch?vez-Fumagalli MA, Silva ES, Galdino AS, Duarte MC, Roatt BM, Menezes-Souza D, Teixeira AL, Coelho EAF. Immunogenicity and protective efficacy of a new Leishmania hypothetical protein applied as a DNA vaccine or in a recombinant form against Leishmania infantum infection. Mol Immunol. 2019 02; 106:108-118.
-
Ribeiro PAF, Dias DS, Lage DP, Costa LE, Martins VT, Tavares GSV, Mendon?a DVC, Lima MP, Oliveira JS, Steiner BT, Machado-de-?vila RA, Roatt BM, Ch?vez-Fumagalli MA, Menezes-Souza D, Duarte MC, Teixeira AL, Coelho EAF. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. Cell Immunol. 2018 09; 331:67-77.
-
Ram?rez M, Santos S, Mart?nez O, Rodr?guez R, Miranda E, Ramos-Perez WD, Otero M. Characterization of the immune response elicited by the vaccinia virus L3 protein delivered as naked DNA. Vaccine. 2018 04 05; 36(15):2049-2055.
-
Mart?nez O, Bravo Cruz A, Santos S, Ram?rez M, Miranda E, Shisler J, Otero M. Vaccination with a codon-optimized A27L-containing plasmid decreases virus replication and dissemination after vaccinia virus challenge. Vaccine. 2017 10 20; 35(44):6007-6014.
-
Gupta S, Termini JM, Rivas Y, Otero M, Raffa FN, Bhat V, Farooq A, Stone GW. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model. Vaccine. 2015 Sep 11; 33(38):4798-806.
-
Rose AH, Hoffmann FW, Hara JH, Urschitz J, Moisyadi S, Hoffmann PR, Bertino P. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses. Hum Vaccin Immunother. 2015; 11(9):2305-11.